Cibus, Inc. (Calyxt, Inc.) 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for Calyxt, Inc. (referred to as Cibus in the request metadata, but identified as Calyxt in the document) for the period ended June 30, 2019. Calyxt is an emerging growth company and an accelerated filer, majority-owned by Cellectis S.A. (69.1% ownership). The company focuses on developing healthy food ingredients using proprietary gene-editing technology (TALEN), with its first commercial products being High Oleic Soybean Oil and Meal. The company operates in a single segment: food ingredients.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2019 | Balance Sheet (June 30, 2019) |
|---|---|---|---|
| Revenue | $408,000 | $566,000 | N/A |
| Net Loss | $(9,403,000) | $(16,778,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.29) | $(0.51) | N/A |
| Operating Expenses | $9,900,000 | $17,581,000 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $76,434,000 |
| Total Restricted Cash | N/A | N/A | $1,509,000 |
| Total Assets | N/A | N/A | $103,576,000 |
| Total Liabilities | N/A | N/A | $23,386,000 |
| Accumulated Deficit | N/A | N/A | $(99,223,000) |
Margin Analysis: Gross margin is not representative of future performance as the company recently began commercialization. Cost of revenue ($303,000 for Q2) includes supply chain costs and a reserve for seed returns. Operating margins are negative due to significant R&D and SG&A expenses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 108% quarter-over-quarter (Q2 2019 vs. Q2 2018) and 173% year-to-date, driven by the first commercial sales of High Oleic Soybean products in Q1 2019.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 58% in Q2 and 74% YTD, primarily due to hiring for commercialization and increased stock-based compensation. R&D expenses decreased 16% in Q2 but increased 12% YTD.
- Net Loss Expansion: Net loss increased 24% in Q2 and 40% YTD compared to the prior year periods, reflecting the ramp-up of commercial infrastructure costs.
- Cash Position: Cash and cash equivalents decreased from $93.8 million (Dec 31, 2018) to $76.4 million (June 30, 2019). Net cash used in operating activities was $15.9 million for the six months ended June 30, 2019, compared to $8.8 million in the prior year period.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant expenses and increasing operating losses for the foreseeable future. The company anticipates needing additional funding for product development and commercialization. Based on the cash burn rate, management believes current cash resources ($77.9 million total cash) are sufficient to fund operations through at least early 2021.
Risks and Contingencies:
- Liquidity Risk: The company has an accumulated deficit of $99.2 million and relies on cash on hand or future equity/debt financings. Failure to raise capital could force a delay or discontinuation of operations.
- Commercialization Uncertainty: Significant revenue generation is contingent on the full commercialization of High Oleic Soybean products and future candidates, which involves regulatory and market risks.
- Related Party Dependence: The company is a majority-owned subsidiary of Cellectis, which provides management services, guarantees the headquarters lease, and owns key intellectual property (TALEN technology). Financial results may not reflect standalone performance.
- Commodity Price Risk: The company is exposed to commodity price fluctuations. A 10% increase in commodity futures prices would impact financial condition by approximately $1.2 million.
Investor Verification Checklist
- Verify the timeline and volume of future sales for High Oleic Soybean Oil and Meal to assess revenue sustainability.
- Review the specific terms of the management services agreement and royalty obligations with Cellectis S.A.
- Monitor cash burn rates and the timeline for any potential follow-on equity offerings or debt financings.
- Assess the progress of regulatory approvals for future product candidates (e.g., High Fiber Wheat).
- Confirm the status of the $19.0 million committed grain purchase agreements and their impact on future inventory costs.